METHODS: All men (n[1,539) with PC receiving ADT who had a FSH within 2 years before starting ADT were identified in the Veterans Affairs (VA) Health System between 1999 and 2018. Men with MACE prior to ADT were excluded for the MACE outcome (n [477). FSH was dichotomized as low/normal ( 8 IU/mL; n[878) and high (>8 IU/mL; n[661) and as continuous (secondary analysis). Differences in time from ADT to MACE and ADT to ACM by FSH were tested via the log-rank test and Cox proportional hazards. Multivariable models were adjusted for age, year, race, BMI, Charlson Comorbidity Index, primary treatment, biopsy grade group, PSA, time from FSH to ADT, and chemotherapy (yes/no). The MACE model was further adjusted for testosterone level (lowest, middle and highest tertile vs. missing).
2 , p[0.004) vs. those with low/normal FSH. There were 337 (51%) men with high FSH and 381 (43%) with low/normal FSH who died over a median 86 mos 
INTRODUCTION AND OBJECTIVES:
The aim of this study was to investigate the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of cognitive decline in Asian men with prostate cancer (PC) by employing a nationwide population-based data set.
METHODS: A population-based cohort of 24,464 men with newly diagnosed PC between 2,000 and 2008 was selected from the Taiwan National Health Insurance (NHI) Database. After excluding patients with ADT exposure, other malignancy, and diagnosis of the outcome of interests before the index date, 17,425 PC patients were included for final analysis. Patients were classified as ADT group (n[12,740) or non-ADT comparison group (n [4,685) . A time-dependent exposure model was used, which allowed investigators to calculate the exposure period from the different usage of various kinds of ADT. The Multivariable Cox proportional hazard model with time-dependent covariates was used to estimate adjusted hazard ratios (HRs) of cognitive decline associated with different kinds of ADT treatment.
RESULTS: Among 17,425 men with PC, there was a statistically significant association between ADT use and risk of overall cognitive decline (hazard ratio, HR, 1.51; 95% CI, 1.31-1.74). ADT users had a 1.83-fold risk of Parkinson's disease and 1.38-fold risk of dementia correspondingly (95% CI [ 1.44-2.34 and 1.17-1.63, respectively). After further investigating the subtypes of dementia, non-Alzheimer's dementia (non-AZD) rather than Alzheimer's dementia (AD) demonstrated a significant higher association with ADT use. Anti-androgen alone were associated with subsequent AD, non-AZD, and Parkinson disease. In addition, an increased risk of Parkinson's disease was also observed in combined androgen blockade (CAB) group. The duration of ADT showed no association with cognitive dysfunction.
CONCLUSIONS: This population-based study demonstrated that antiandrogens alone was associated with a higher risk of overall cognitive dysfunction, overall dementia, and Parkinson disease. The risk of overall cognitive decline and Parkinson's disease also appeared to be higher in CAB group. Different ADT therapies may have unequally impact on cognitive dysfunction.
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PD15-03 THE EFFICACY AND FEASIBILITY OF RADIATION THERAPY TO THE PRIMARY TUMOR IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Naoki Fujita*, Masaki Momota, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Hirosaki, Japan; Hiroyuki Ito, Hachinohe, Japan; Takahiro Yoneyama, Yasuhiro Hashimoto, Hirosaki, Japan; Kazuaki Yoshikawa, Mutsu, Japan; Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: Several studies reported the efficacy and feasibility of radiation therapy (RT) to the primary tumor in patients with metastatic prostate cancer. However, there is no study in patients with metastatic castration resistant prostate cancer (mCRPC). We hypothesized that RT to the prostate would improve overall survival (OS) in mCRPC patients. Therefore, the aim of the present study was to evaluate the efficacy and feasibility of RT to the primary tumor in patients with mCRPC.
METHODS: A total of 87 patients with mCRPC were examined retrospectively. Patients were divided into two groups between patients with RT after CRPC diagnosis (RT group) and without RT (non-RT group). We compared oncological outcomes, including cancer-specific survival (CSS) and OS between two groups. We performed multivariate Cox regression analyses using inverse probability of treatment weighting (IPTW) method to evaluate the impact of RT on CSS and OS.
RESULTS: Median age at CRPC diagnosis was 74 years, and median follow-up periods after CRPC diagnosis were 28 months in this cohort. Of the 87 patients, 28 (32%) were treated with RT to the primary tumor after CRPC diagnosis. Median time from CRPC diagnosis to RT initiation were 18 months. The rates of adverse events related with RT in any grade and !grade 3 were 60% and 20%, respectively. The median PSA decline rate for RT was 24%. Twelve (43%) patients
